Precision Nanomedicine Using Dual PET and MR Temperature Imaging–Guided Photothermal Therapy

Abstract

Imaging-based techniques have enabled the direct integration of noninvasive imaging with minimally invasive interventions such as photothermal therapy (PTT) to improve the precision of treatment. Here, we investigated the feasibility of PTT for ovarian cancer (OvC) under the guidance of positron emission tomography (PET) and magnetic resonance temperature imaging (MRTI) using copper sulfide nanoparticles (CuS NPs). The tumor distribution of the CuS NPs after systemic administration was assessed by using highly sensitive, quantifiable PET imaging. Two wavelengths of near-infrared (NIR) lasers—808 and 980 nm—were tested for PTT using non-invasive MRTI real-time monitoring. The in vivo studies revealed that the 980-nm NIR laser had better photothermal effects than the 808-nm NIR laser. These results were in accord with the histological findings. In vivo PTT using CuS NPs combined with 980-nm laser irradiation achieved significant tumor ablation compared to no treatment control in both subcutaneous (p=0.007) and orthotopic (p<0.001) models of OvC with regard to the percentage of necrotic damage. Our results indicate that real-time monitoring of the accuracy of PTT is a promising approach for future clinical translation of this emerging thermal ablation technique.

Radiolabeled inorganic nanoparticles for positron emission tomography imaging of cancer: an overview

“…This work was further extended by the same group of authors to establish the suitability of intrinsically radiolabeled 64 CuS nanoparticles as a theranostic agent in different tumor models 107–109 and for sentinel lymph node mapping. 110 Also, folic acid conjugated 64 CuS-PEG nanoparticles were synthesized by the same group for PET imaging and photothermal ablation therapy of folate receptor positive tumors.…”

Osteotropic Radiolabeled Nanophotosensitizer for Imaging and Treating Multiple Myeloma

“…The promise of nanomedicine in cancer therapy resides in the ability to deliver high payloads of drugs to cancer, amplify imaging signals, − optimize combination therapies, and improve theranostic strategies. − As vectors for drug delivery, nanoparticles (NPs) have the coveted advantages of modifying drug pharmacokinetics in vivo , − controlling drug release, − optimizing blood circulation half-lives, improving biodistribution profiles, increasing tissue permeability, − and enhancing metabolic stability of drugs. , For imaging applications, some NPs exhibit intrinsic properties that facilitate their use as imaging agents. − Typical examples include light-emitting quantum dots for fluorescence imaging and ultrasmall superparamagnetic iron oxide particles as magnetic resonance imaging (MRI) contrast agents . Despite these benefits, clinical translation of most nanoparticle-based therapies and imaging agents has remained a challenge, in part due to the low percentage of injected dose that reaches the target tissues.…”

Radiolabeling of Theranostic Nanosystems

“…In the orthotopic ovarian cancer mice model, this resulted in effective therapeutic outcome. [58] To improve on the previous results in terms of the tumor availability of the nanoparticle, RGDfK peptides were attached to the CuS nanoparticles to target the αvβ3 integrins and labelled with 64 Cu in a chelator-free fashion as before. For the therapy a lower wavelength of 808 nm at 3 W/cm 2 for 2 min was used which increased the tumor temperature to 58.1 °C and resulted in 98% tumor tissue necrosis in U87 tumor-bearing mice.…”